Figure 8. G6PD expression, prognostic value, and enriched pathways in LUAD tissues. (A) IHC staining of G6PD in normal and LUAD tissues from the HPA database. (B) The prognostic analysis of G6PD in LUAD patients. (C) GSEA of the enriched pathways in LUAD patients with high G6PD expression (D) The enriched immune-related pathways in LUAD patients by ssGSEA. (E) The level of immune cell infiltration of 22 subpopulations of immune cells in the G6PD high and low groups based on the CIBERSORT algorithm. (F) The levels of immune checkpoint molecules in the G6PD high and low groups.